Global WholeHealth Partners Corp (OTC:GWHP) Has Been Able to Pay Off All Convertible Notes and Now Has an ATM With EMC2 for up to $100,000,000 According to the S1 Filed in July 2020
Global has found capital from longer term investments through the ATM by EMC2.
San Clemente, CA, April 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Eliminating all the convertible notes represents a significant milestone for Global WholeHealth Partners Corp (OTC: GWHP), as now, Global has found capital from longer term investments through the ATM by EMC2. Global is building a stronger financial base, by eliminating debt.
Global WholeHealth Partners Corp (OTC: GWHP) is moving the company forward with better financing. With the ATM, Global is ready to expand and grow as needed. ATM financing strategies provide control on the timing and amount of capital raised. This allows Global to raise capital on the terms that Global chooses, including when and if the ATM is utilized. This allows Global to opportunistically take advantage of increases in the share price and means that Global does not have to time the capital raise perfectly, in effect "averaging in" to their own share price; this strategy is best suited for Global with the great expectations Global has for the future.
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
The strong growth outlook comes from Global leading the way in the fight against CoViD19, by offering 15 Minute Rapid IgG/IgM Tests for Venous Blood, & Fingertip Blood (POC), and 50 Minute rt-PCR Tests for CoViD19 with All the Tests Being FDA EUA Authorized, one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2.
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp., said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offeing FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like Rapid Ebola, ZIKA, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests. Global is planning to be able to offer an Antigen Rapid Test soon.”
Call 1-877-568-GWHP (4947) to become a distributor or buy FDA EUA Authorized SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma Rapid Test kits, or the Point of Care IgG/IgM fingertip blood format or the rtPCR test, or the EUA Antigen Rapid test.
For more details: https://gwhpcorp.com
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Press Room Open (Press, Speaker or Exhibitor badge required)
Marketing Open-Source Solutions â€“ Building a Customer Base without Breaking the Bank
From Managing Resources to Managing Performance